Display options
Cite
Lenderking WR, Anatchkova M, Pokrzywinski R, et al. Measuring health-related quality of life in patients with rare disease. J Patient Rep Outcomes. 2021;5(1):61doi: 10.1186/s41687-021-00336-8.
Lenderking, W. R., Anatchkova, M., Pokrzywinski, R., Skalicky, A., Martin, M. L., & Gelhorn, H. (2021). Measuring health-related quality of life in patients with rare disease. Journal of patient-reported outcomes, 5(1), 61. https://doi.org/10.1186/s41687-021-00336-8
Lenderking, William R, et al. "Measuring health-related quality of life in patients with rare disease." Journal of patient-reported outcomes vol. 5,1 (2021): 61. doi: https://doi.org/10.1186/s41687-021-00336-8
Lenderking WR, Anatchkova M, Pokrzywinski R, Skalicky A, Martin ML, Gelhorn H. Measuring health-related quality of life in patients with rare disease. J Patient Rep Outcomes. 2021 Jul 20;5(1):61. doi: 10.1186/s41687-021-00336-8. PMID: 34283357; PMCID: PMC8292508.
Copy Download .nbib Format: NLM
Share it on

J Patient Rep Outcomes. 2021 Jul 20;5(1):61. doi: 10.1186/s41687-021-00336-8.

Measuring health-related quality of life in patients with rare disease.

Journal of patient-reported outcomes

William R Lenderking, Milena Anatchkova, Robin Pokrzywinski, Anne Skalicky, Mona L Martin, Heather Gelhorn

Affiliations

  1. Patient-centered Research, Evidera, 500 Totten Pond Rd. Fifth Floor, Waltham, MA, 02451, USA. [email protected].
  2. Patient-centered Research, Evidera, Bethesda, MD, USA.
  3. Patient-centered Research, Evidera, Seattle, WA, USA.

PMID: 34283357 PMCID: PMC8292508 DOI: 10.1186/s41687-021-00336-8

Abstract

BACKGROUND: There has been a growing emphasis on health-related quality of life (HRQoL) as an important outcome in rare disease drug development, although its assessment may be useful outside the drug development context, including in clinical applications or natural history studies. Central to assessing quality of life in health research is utilizing outcome measures that capture symptoms and impacts of the disease and treatment that are important and relevant to patients. Identifying and implementing valid and reliable tools to measure HRQoL in rare diseases poses unique challenges that often require creative solutions.

MAIN BODY: In this commentary, we explore some of the challenges in HRQoL assessment in rare disease, propose solutions, and consider regulatory issues. Some of the solutions discussed entail the use of item banks, adapting existing measures from phenotypically similar disease contexts, use of multi-domain measurement indices, and adapting methods for assessing content validity of existing measures. Current regulatory considerations are discussed and resources outlined.

CONCLUSION: Quality of life may be the most important endpoint for patients with rare diseases, and the challenges of valid assessment require effort and innovative thinking specific to each context to improve measurement and clinical outcomes.

© 2021. The Author(s).

Keywords: Clinical outcome assessment (COA); Disease-specific; Embedded interviews; FDA; HRQoL; Item banks; Measure adaptation; Multi-dimensional responder index; Rare disease

References

  1. Orphanet J Rare Dis. 2017 Nov 2;12(1):171 - PubMed
  2. Value Health. 2019 Aug;22(8):925-930 - PubMed
  3. Dev Med Child Neurol. 2011 May;53(5):394-404 - PubMed
  4. J Patient Rep Outcomes. 2020 Jul 16;4(1):61 - PubMed
  5. Value Health. 2017 Jul - Aug;20(7):838-855 - PubMed
  6. Clin Ther. 2016 Apr;38(4):778-93 - PubMed
  7. Mov Disord Clin Pract. 2019 Jan 22;6(2):139-149 - PubMed
  8. J Patient Rep Outcomes. 2019 Feb 4;3(1):6 - PubMed
  9. Am J Med Genet. 2000 Apr 24;91(5):368-76 - PubMed
  10. J Patient Rep Outcomes. 2019 Jul 23;3(1):44 - PubMed
  11. Orphanet J Rare Dis. 2020 Jun 3;15(1):134 - PubMed
  12. Orphanet J Rare Dis. 2019 Jul 12;14(1):174 - PubMed
  13. Orphanet J Rare Dis. 2019 Feb 8;14(1):36 - PubMed
  14. Lancet. 2019 Aug 10;394(10197):478-487 - PubMed
  15. Sarcoma. 2017;2017:6868030 - PubMed

Publication Types